Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Early Sepsis Detection Using NEWS2 and Circulating H3.1 Nucleosomes in Emergency Departments (DETECSEPS)

11. november 2026 opdateret af: Assistance Publique - Hôpitaux de Paris

Real-life Evaluation of the Impact of Early Detection of Sepsis With the NEWS2 Clinical Alert Score Combined to Circulating Concentrations of the H3.1 Nucleosome, on the Care Pathway of Adults Presenting to the Emergency Department With a Proven or Strongly Suspected Infection

DETECSEPS is a multicentre, randomized, open-label trial sponsored by Assistance Publique - Hôpitaux de Paris, under the scientific leadership of IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center, led by Professor Djillali Annane.

The study evaluates whether an early sepsis detection strategy combining the National Early Warning Score 2 (NEWS2) and circulating H3.1 nucleosome concentrations improves care pathways compared with usual care in adults presenting to emergency departments with suspected or confirmed infection and at least one risk factor for sepsis.

The strategy aims to support timely recognition and management of sepsis and to identify patients suitable for discharge with ambulatory follow-up when hospital admission is not otherwise indicated. The study will assess care pathway optimization at 24 hours, clinical outcomes, health-related quality of life, return to usual activities, and economic and environmental outcomes.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

DETECSEPS will enrol 1,000 adults across participating emergency departments. Participants will be randomized to either a diagnostic and management strategy guided by NEWS2 and circulating H3.1 nucleosome concentrations or usual care.

In the intervention group, the combined algorithm will guide clinical management and disposition according to the approved study protocol. The description of the algorithm will specify the actions associated with each combination of NEWS2 and H3.1 categories, including discharge with ambulatory follow-up, hospital admission, early sepsis management, and assessment for intensive care admission.

In the usual-care group, management will follow routine clinical practice. Research H3.1 results will not be disclosed to treating clinicians. The record will distinguish any NEWS2 score calculated specifically for research from physiological measurements and assessment tools available during routine care.

The primary outcome is the proportion of participants with an optimized care pathway at 24 hours. Participants will be followed for six months.

IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center is responsible for the scientific leadership of the study. Assistance Publique - Hôpitaux de Paris is the study sponsor.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

1000

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

      • Boulogne-Billancourt, Frankrig
        • Hôpital Ambroise Paré - AP-HP
        • Kontakt:
      • Lyon, Frankrig
        • Hôpital de la Croix Rousse - HCL
        • Kontakt:
      • Lyon, Frankrig
      • Lyon, Frankrig
      • Paris, Frankrig
        • Hôpital Bichat - AP-HP
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria

  1. All genders patients

  2. Aged of 18 years or older

  3. Proven or suspected infection

  4. At least one risk factor for sepsis (cf HAS recommendations) :

    • Age/frailty : >65 year; Clinical Frailty Scale ≥5; postpartum; Cognitive or motor disabilities; Implantable medical device; Recent surgery

    • Inborn immune deficit

    • Acquired immune deficit :

      • Diseases related : Cancer, Transplant patient, Chronic inflammatory or autoimmune disease, HIV, Asplenic anatomical or functional (Sickle cell disease)
      • Treatment related : Long-term corticotherapy, chemotherapy, Biotherapy, Cell therapy, radiotherapy, Immunosuppressive drugs,
    • Non immune disorders : Cirrhosis, chronic liver disease, chronic renal insufficiency, chronic cardiac failure, diabetes with complication or uncontrolled, malnutrition, previous episode of sepsis

  5. Informed consent

Exclusion Criteria:

  1. Refused to consent participating in the study,
  2. Any condition for which patient's primary physician will consider inappropriate enrolling patient in the study,
  3. Previous enrolment
  4. Pregnancy

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Diagnostisk
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: NEWS2 and H3.1-guided diagnostic and management strategy

Clinical management and disposition will be guided by a prespecified algorithm combining NEWS2 and circulating H3.1 nucleosome concentrations. Decisions will follow the thresholds and management rules specified in the protocol.

Upon randomization, NEWS2 score and plasma level of H3.1 will be provided to the investigator and healthcare staff to guide management as per decision tree below :

  • If NEWS2 ≤2 AND H3.1 ≤50 ng/ml, the progression to sepsis is very unlikely or unlikely and the patient can be discharged home with ambulatory follow-up via teleconsultation.
  • If NEWS2 ≥5 and H3.1 ≥740 ng/ml, the progression to sepsis is likely or very likely and the 3-hour bundle of the Surviving Sepsis Campaign will be implemented and admission to the ICU within 6 hours of arrival at Emergency Department is required.
  • In any other case, patients will be monitored in the emergency department and NEWS 2 and plasma H3.1 level are recorded again at 3 hours.

This biomarker levels will be measured with Nu.Q® NETs/H3.1 automated system.

The result will not be disclosed to the investigators and healthcare staff in the control arm

The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system:

  1. respiration rate
  2. oxygen saturation
  3. systolic blood pressure
  4. pulse rate
  5. level of consciousness or new confusion
  6. temperature

The result will not be disclosed to the investigators and healthcare staff in the control arm

Andet: Usual care

Comparator arm description: Participants will receive usual diagnostic assessment and clinical management. H3.1 nucleosome concentrations will be measured for research purposes, but results will not be disclosed to treating clinicians.

This biomarker levels will be measured with Nu.Q® NETs/H3.1 automated system.

The result will not be disclosed to the investigators and healthcare staff in the control arm

The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system:

  1. respiration rate
  2. oxygen saturation
  3. systolic blood pressure
  4. pulse rate
  5. level of consciousness or new confusion
  6. temperature

The result will not be disclosed to the investigators and healthcare staff in the control arm

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of patients with optimized care pathway
Tidsramme: 24 hours after inclusion

The best care pathway is defined by: discharge to home in the absence of confirmed sepsis, or hospitalization whenever any other reason than sepsis will mandate hospital admission

If sepsis is confirmed:

  • Implementation of good clinical practice recommendations within 3 hours of arrival at ED (3-hour bundle of the Surviving Sepsis Campaign & HAS recommendations)
  • ICU admission within 6 hours of arrival at ED
24 hours after inclusion

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Death rate
Tidsramme: At 6 months
At 6 months
Cumulative incidence of direct ICU admission
Tidsramme: Up to 6 months
Up to 6 months
Cumulative incidence of secondary ICU admission
Tidsramme: Up to 6 months

ie after admission to ward

Up to 6 months
Proportion of patients with cognitive, psychological, or physical sequelae
Tidsramme: Up to 6 months
Up to 6 months
Proportion of patients requiring renal, respiratory, or cardiovascular support
Tidsramme: Up to day 7

Organ support is defined as needing either respiratory, cardiovascular or renal support. Respiratory support is defined as high flow oxygen, non-invasive or invasive ventilation, extracorporeal membrane oxygenation or CO2 removal. Cardiovascular support is defined as ongoing infusion of any dose of any vasopressor or inotrope drug, or mechanical circulatory assistance. Renal support is defined by the requirement of renal replacement therapy regardless of treatment modalities. We will also compute the number of days free of organ support up to 7 and 28 days, with higher score indicating faster recovery

Up to day 7
Proportion of patients requiring renal, respiratory, or cardiovascular support
Tidsramme: Up to day 28

Organ support is defined as needing either respiratory, cardiovascular or renal support. Respiratory support is defined as high flow oxygen, non-invasive or invasive ventilation, extracorporeal membrane oxygenation or CO2 removal. Cardiovascular support is defined as ongoing infusion of any dose of any vasopressor or inotrope drug, or mechanical circulatory assistance. Renal support is defined by the requirement of renal replacement therapy regardless of treatment modalities. We will also compute the number of days free of organ support up to 7 and 28 days, with higher score indicating faster recovery

Up to day 28
Time to discharge to home
Tidsramme: Up to 6 months
Up to 6 months
Time to resume previous social and professional activities
Tidsramme: Up to 6 months
Up to 6 months
Quality of life - EQ-5D-5L
Tidsramme: At 6 months

The EQ-5D-5L is a patient-reported questionnaire assessing health-related quality of life across five dimensions, with higher index and EQ VAS scores indicating better health status

At 6 months
Quality of life - SF36
Tidsramme: At 6 months

The SF-36 is a 36-item patient-reported questionnaire assessing health-related quality of life across eight physical and mental health domains, with higher scores indicating better health status and functioning.

At 6 months
Cost of strategies and care pathways
Tidsramme: At 6 months

Costs of strategies and care pathways at 6 months with and without early H3.1 concentrations and the NEWS2 clinical score, incremental cost-effectiveness ratio calculated by the ratio of the difference in costs to the difference in survival without sequelae and without organ failure at 6 months.

At 6 months
Proportion of cases for which the combined diagnostic protocol is applied as intended
Tidsramme: Up to 6 months

e.g., correct use of NEWS2 and H3.1 nucleosome testing

Up to 6 months
Proportion of test results available below a meaningful clinical duration to allow for patient management.
Tidsramme: Up to 6 months
Up to 6 months
Proportion of appropriate integration of tests results within clinical workflow
Tidsramme: Up to 6 months
Up to 6 months
Proportion of avoided hospitalization among patients receiving the intervention
Tidsramme: Up to 6 months
Up to 6 months
Evolution of the proportion of eligible patients included over time
Tidsramme: Up to 6 months
Up to 6 months
Environmental impact of study-related procedures
Tidsramme: Up to 6 months

The environmental footprint of each component of the research process will be assess, including:

  • Biological sampling: Biomarkers will be measured from routine care tubes, avoiding the use of dedicated research tubes, which often expire unused and contribute to waste.
  • Patient transport: No additional on-site visits will be required for the study, limiting travel-related emissions (Lyle et al., BMJ, 2009).
  • Study documentation: Digital consent forms (e-consent) will be preferred. When choosing between paper or electronic formats, the environmental impact of printing, document replacement after amendments, and digital storage will be considered.

All study procedures will be reviewed according to the guidance proposed by Griffiths et al. (BMJ Open, 2024), which identified high-impact areas in clinical trials. The goal is to apply these recommendations throughout the study.

Up to 6 months
Life cycle analyse (LCA)
Tidsramme: Up to 6 months

Life cycle analyses (LCA) of the new algorithm and its associated device. It will be based on the Life Cycle Assessment (LCA) framework proposed by Ashby (Materials and the Environment, 2013), using Granta EduPack® software tools.

Up to 6 months
LCA comparison of the two clinical strategies
Tidsramme: Up to 6 months

The two clinical strategies will be compared using LCA to assess their respective environmental impacts from patient inclusion to the end of follow-up. This approach is inspired by previous work (Makhloufi et al., Nephrol Dial Transplant, 2024), integrating medical and ecological outcomes.

The average carbon emissions and water consumption between the two groups will be compared by collecting all activities from the time of inclusion until the end of follow-up in the study.

Up to 6 months

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Circulating levels of C-reactive protein, procalcitonin, NETs, neutrophil degranulation markers, cytokines and chemokines
Tidsramme: At baseline, day 1 and day 7
At baseline, day 1 and day 7
Multi-omic profile
Tidsramme: At baseline

Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

At baseline
Multi-omic profile
Tidsramme: At day 1

Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

At day 1
Multi-omic profile
Tidsramme: At day 7

Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

At day 7
Innate immune cells activation markers and sub-populations
Tidsramme: At baseline

Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

At baseline
Innate immune cells activation markers and sub-populations
Tidsramme: At day 1

Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

At day 1
Innate immune cells activation markers and sub-populations
Tidsramme: At day 7

Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

At day 7

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studiestol: Djillali Annane, MD PhD, IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center, AP-HP, Université Paris-Saclay

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

2. december 2027

Studieafslutning (Anslået)

1. juni 2028

Datoer for studieregistrering

Først indsendt

30. oktober 2026

Først indsendt, der opfyldte QC-kriterier

11. november 2026

Først opslået (Faktiske)

17. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • APHP260617

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

According to DETECSEPS consortium data management plan, upon request to IHU SEPSIS and to APHP

IPD-delingstidsramme

Within 6 months from publication of the study results

IPD-delingsadgangskriterier

Upon request to IHU SEPSIS and to APHP according to the data management plan of the Consortium

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .